Australia: Incannex funds clinical programmes into 2025 with institutional placement

Incannex Healthcare, a clinical-stage pharmaceutical company developing novel cannabinoid pharmaceuticals and psychedelic therapies, has undertaken an institutional placement totalling approximately A$13m (US$8.9m) at A$0.205 per share. Each participant will be offered one option for no additional consideration for every new share. On completion of the placement, Incannex will have a pro-forma cash position of around…

You must be a HMI Subscriber to view this content.

Subscribe Now »